21 July 2020
Advs. Ben Sandler and Barry Levenfeld represented orthologics company Bioventus in its investment in the Israeli medical device company Cartiheal, including in signing an option to buy it. Assisted alongside David Roness, Ofir Levy, Daniel Marcovici, Daniel Green, Eli Greenbaum, Guy Fuhrer, Miriam Friedmann, Shira Teger, Tali Har-Oz, Hadar Stein, Chaim Cohen, Chaya Alexandra Y.N. Kong, Sophy Litvin, Nir Kamhi, Ofir Paz, Shmuel Brill and interns Noah Levy, Katya Kagantsov and Danya Sakols.

Advs. Ben Sandler and Barry Levenfeld represented orthologics company Bioventus in its investment in the Israeli medical device company Cartiheal, including in signing an option to buy it. Assisted alongside David Roness, Ofir Levy, Daniel Marcovici, Daniel Green, Eli Greenbaum, Guy Fuhrer, Miriam Friedmann, Shira Teger, Tali Har-Oz, Hadar Stein, Chaim Cohen, Chaya Alexandra Y.N. Kong, Sophy Litvin, Nir Kamhi, Ofir Paz, Shmuel Brill and interns Noah Levy, Katya Kagantsov and Danya Sakols.


09 July 2020
Adv. Tamar Tavory recently joined our firm as special counsel and will be strengthening the firm’s digital health practice, with a particular focus on telehealth, AI in medicine, medical research, and secondary use of medical data.

Adv. Tamar Tavory recently joined our firm as special counsel and will be strengthening the firm’s digital health practice, with a particular focus on telehealth, AI in medicine, medical research, and secondary use of medical data.


02 July 2020
Advs. Barry Levenfeld, Adrian Daniels, Noah Zivan, Vered Glaubach and intern Nitzan Bigman represented Barclays in their role as underwriters in the IPO of clinical-stage bio-pharmaceutical company PolyPid on Nasdaq, in which $60 million were raised. They were joined by Shira Lahat, Daniel Green, Miriam Friedmann, Sophy Litvin, Dr. Eran Lempert, Assaf Mesica and Shai Margalit.

Advs. Barry Levenfeld, Adrian Daniels, Noah Zivan, Vered Glaubach and intern Nitzan Bigman represented Barclays in their role as underwriters in the IPO of clinical-stage bio-pharmaceutical company PolyPid on Nasdaq, in which $60 million were raised. They were joined by Shira Lahat, Daniel Green, Miriam Friedmann, Sophy Litvin, Dr. Eran Lempert, Assaf Mesica and Shai Margalit.


14 June 2020
Advs. Simon Weintraub, Daniel Green, Shira Teger and Tali Har-Oz represented Prilenia Therapeutics in a Series A financing round in which it raised 62.5 million dollars. The new funds will be used for two late-stage trials, which could lead to the registration of pridopidine for the treatment of HD and ALS.

Advs. Simon Weintraub, Daniel Green, Shira Teger and Tali Har-Oz represented Prilenia Therapeutics in a Series A financing round in which it raised 62.5 million dollars. The new funds will be used for two late-stage trials, which could lead to the registration of pridopidine for the treatment of HD and ALS.


17 March 2019
Advs. Barry Levenfeld, Ben Sandler, Evan Schendler, Alona Toledano, Ofir Levy, Shay Fahima, Yoheved Novogroder Shoshan, Daniel Green, Miriam Friedmann, Tali Har-Oz and the interns Itamar Ben David, Hadar Stein and Elad Cohen represented the med-tech giant Stryker in the acquisition of Orthospace Ltd, an Israeli company that has developed a device for treating serious shoulder pain, for $220 million. 

Advs. Barry Levenfeld, Ben Sandler, Evan Schendler, Alona Toledano, Ofir Levy, Shay Fahima, Yoheved Novogroder Shoshan, Daniel Green, Miriam Friedmann, Tali Har-Oz and the interns Itamar Ben David, Hadar Stein and Elad Cohen represented the med-tech giant Stryker in the acquisition of Orthospace Ltd, an Israeli company that has developed a device for treating serious shoulder pain, for $220 million. 


03 October 2013

Yigal Arnon & Co. in cooperation with IATI, invite Hi-Tech & Life Science Start-ups to join us in the event: “The Ins-and-Outs of the Due Diligence Process in Investment Transactions”

Yigal Arnon & Co. in cooperation with IATI (Israel Advanced Technology Industries) invite Hi-Tech & Life Science Start-ups to join us in the event: “The Ins-and-Outs of the Due Diligence Process in Investment Transactions”, October 23, 2013, Yigal Arnon & Co. offices.

Yigal Arnon & Co. in cooperation with IATI (Israel Advanced Technology Industries) invite Hi-Tech & Life Science Start-ups to join us in the event: “The Ins-and-Outs of the Due Diligence Process in Investment Transactions”, October 23, 2013, Yigal Arnon & Co. offices.


13 August 2013

Yigal Arnon & Co. represents Johnson & Johnson, Takeda Pharmaceuticals and OrbiMed, to establish a Biotech Incubator

Advocates Barry Levenfeld, Harry Kirsh, Yuval Shalhevet, Zohar Nevo and Noam Enk represents the winning bidding consortium, consisting of Johnson & Johnson, Takeda Pharmaceuticals (the first Japanese Pharmaceutical Company to invest in Israel) and the healthcare fund OrbiMed Israel, for the establishment of an OCS-supported biotechnological incubator intended to encourage the creation and support of pharmaceutical and medical device companies.

Advocates Barry Levenfeld, Harry Kirsh, Yuval Shalhevet, Zohar Nevo and Noam Enk represents the winning bidding consortium, consisting of Johnson & Johnson, Takeda Pharmaceuticals (the first Japanese Pharmaceutical Company to invest in Israel) and the healthcare fund OrbiMed Israel, for the establishment of an OCS-supported biotechnological incubator intended to encourage the creation and support of pharmaceutical and medical device companies.


28 May 2013

Yigal Arnon & Co. represented Aegis as the sole book-running manager for Alcobra Ltd.’s initial public offering on Nasdaq.

Advs. Barry Levenfeld, Eric Spindel, Avigail Frisch and Noam Enk represented Aegis for Alcobra Ltd.'s initial public offering on Nasdaq. Alcobra Ltd., headquartered in Israel, is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug to treat Attention Deficit Hyperactivity Disorder.
 

Advs. Barry Levenfeld, Eric Spindel, Avigail Frisch and Noam Enk represented Aegis for Alcobra Ltd.'s initial public offering on Nasdaq. Alcobra Ltd., headquartered in Israel, is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug to treat Attention Deficit Hyperactivity Disorder.
 


04 November 2012
Advocates Barry Levenfeld, Ben Sandler, Harry Kirsh, Avigail Frisch and Zohar Nevo represented Stryker, an U.S.-based leader in worldwide orthopedic medical technology in the acquisition  of the Israeli company Surpass Medical, which develops and commercializes next-generation flow diversion technology to treat brain aneurysms, for $135 million.

Advocates Barry Levenfeld, Ben Sandler, Harry Kirsh, Avigail Frisch and Zohar Nevo represented Stryker, an U.S.-based leader in worldwide orthopedic medical technology in the acquisition  of the Israeli company Surpass Medical, which develops and commercializes next-generation flow diversion technology to treat brain aneurysms, for $135 million.


23 April 2012
Yigal Arnon & Co., BDO and The Luzzatto Group continued the tradition and cooperated again in the 7th High-tech Conference that took place on April 23, 2012, at the Dan Hotel in Tel Aviv. Adv. Barry Levenfeld lectured on The Next Big Exit:  Preparing Your Hi Tech Company for IPO or Acquisition.  
Yigal Arnon & Co., BDO and The Luzzatto Group continued the tradition and cooperated again in the 7th High-tech Conference that took place on April 23, 2012, at the Dan Hotel in Tel Aviv.
Adv. Barry Levenfeld lectured on The Next Big Exit:  Preparing Your Hi Tech Company for IPO or Acquisition.

 


Pages

Recognition

Subscribe for updates and news